You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽升藥業(300485.SZ)一季度扣非淨利潤預降10%-40%
格隆匯 04-12 16:08

格隆匯4月12日丨賽升藥業(300485.SZ)公佈,預計2022年第一季度歸屬於上市公司股東的淨利潤10178.38萬元-11450.67萬元,同比增長140%-170%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1528.2萬元-2,292.3萬元,同比下降10%-40%。

2022年第一季度業績同比增長的主要原因是:1、報吿期內,由於公司按照新金融工具準則確認的金融資產公允價值變動收益及聯營企業投資收益增加所致,公司投資的金融資產主要為生物醫藥、醫療器械等與公司主營業務相關的公司以及醫藥健康專業投資基金,其中公司直接或間接投資的生物醫藥、醫療器械以及與公司主營業務相關公司按照新金融工具準則確認的公允價值變動收益約為7000萬元,聯營企業投資收益約為2000萬元。

2、受國內疫情防控影響,公司預計2022年第一季度歸屬於上市公司股東的扣除非經常性損益的淨利潤比上年同期下降,主要原因是公司2022年第一季度產品銷售收入較上期下降、在研品種研發投入同比增長及新增固定資產折舊增加所致。

預計2022年一季度公司非經常性損益總額約9000萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account